Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to
assess the safety and tolerability of single doses of NNC9204-1706 administered
subcutaneously in male subjects being overweight or with obesity.